

Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

Stefania Tognin^{1,2,31}, Hendrika H. van Hell^{*,3,31}, Kate Merritt¹, Inge Winter-van Rossum³, Matthijs G. Bossong³, Matthew J. Kempton¹, Gemma Modinos¹, Paolo Fusar-Poli^{1,4,5}, Andrea Mechelli^{1,6}, Paola Dazzan¹, Arijia Maat³, Lieuwe de Haan⁶, Benedicto Crespo-Facorro^{7,8,9}, Birte Glenthøj^{10,11}, Stephen M. Lawrie¹², Colm McDonald¹³, Oliver Gruber¹⁴, Therese van Amelsvoort¹⁵, Celso Arango¹⁶, Tilo Kircher¹⁷, Barnaby Nelson^{18,19}, Silvana Galderisi²⁰, Rodrigo Bressan²¹, Jun S. Kwon²², Mark Weiser^{23,24}, Romina Mizrahi^{25–27}, Gabriele Sachs²⁸, Anke Maatz²⁹, René Kahn^{3,30} and Phillip McGuire^{1,2,5}; the PSYSCAN Consortium**

¹Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; ²Outreach and Support in South London (OASIS), South London and Maudsley NHS Foundation Trust, London, UK; ³Department of Psychiatry, University Medical Center Utrecht Brain Center, Utrecht, the Netherlands; ⁴Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; ⁵National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK; ⁶Department Early Psychosis, Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ⁷CIBERSAM, Department of Psychiatry, University Hospital Virgen del Rocío, Sevilla, Spain; ⁸IDIVAL, Marqués de Valdecilla University Hospital, Santander, Spain; ⁹School of Medicine, University of Cantabria, Santander, Spain; ¹⁰Centre for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark; ¹¹Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark; ¹²Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK; ¹³Centre for Neuroimaging & Cognitive Genomics (NICOG), NCBES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland; ¹⁴Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany; ¹⁵Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands; ¹⁶Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain; ¹⁷Department of Psychiatry, University of Marburg, Marburg, Germany; ¹⁸Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; ¹⁹Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia; ²⁰Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy; ²¹Interdisciplinary Lab for Clinical Neurosciences (LiNC), Department of Psychiatry, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil; ²²Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea; ²³Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel; ²⁴Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; ²⁵Institute of Medical Science, University of Toronto, Toronto, Canada; ²⁶Centre for Addiction and Mental Health, Toronto, Canada; ²⁷Department of Psychiatry, University of Toronto, Toronto, Canada; ²⁸Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; ²⁹Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland; ³⁰Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY

³¹These authors contributed equally to this work.

*To whom correspondence should be addressed; Clinical Trial Center, Department of Psychiatry, University Medical Center Utrecht Brain Center, PO Box 85500, 3508 GA Utrecht, The Netherlands; tel: +31 88 755 7247, e-mail: h.h.vanhell-2@umcutrecht.nl

**Full list of authors can be found at the end of the article.

In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of

psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.

Keywords: psychosis/first episode of psychosis/clinical high risk of psychosis/PSYSCAN/neuroimaging/MRI/machine learning/prediction

Introduction

Neuroimaging provides a powerful, noninvasive method to unveil some of the neurobiological mechanisms underlying serious psychiatric disorders such as schizophrenia. In the last 2 decades, researchers have tried to identify brain abnormalities that could aid the prediction of psychosis onset¹⁻⁵ and clinical outcomes⁶⁻¹² in the early stages of psychosis, so that patients can be offered different forms of treatment according to their individual needs. For example, despite several advancements, one of the key challenges in the management of individuals at clinical high risk of psychosis (CHR-P) is that it is not currently possible to identify the subgroups that will subsequently transition to psychosis or that will develop other mental health disorders.^{13,14} Stratification of these subgroups would allow potentially preventative interventions to be selectively offered to these individuals.^{15,16} This is an important task given that one-size-fits-all therapeutic approaches are not particularly effective to prevent the onset of psychosis in this population.¹⁵ Similar limitations are observed in the clinical management of patients who have already experienced a first episode of psychosis (FEP): it is difficult to reliably predict if and when patients will suffer a relapse solely on clinical presentation. If course of illness could be determined early on, targeted intervention could potentially prevent future hospitalizations. Another important challenge in the management and treatment of people with psychosis is that available antipsychotic medications are partially or not effective in about one-third of patients.^{17,18} It is currently not possible to predict which patients will go on to show a poor response to treatment. Identifying these patients would promote earlier access to effective medications for treatment resistant psychosis, such as clozapine,¹⁹ as well as using psychotherapy more effectively.^{20,21} Although some neuroimaging studies have reported findings that may differentiate patients with distinct clinical outcomes,²² these have yet to be externally validated and translated into tools that can be used in clinical practice.^{23,24}

In this context, clinically valid and reliable neuroimaging biomarkers of psychosis onset and outcome have yet to be identified, as the results from structural, functional, and neurochemical magnetic resonance imaging (MRI) studies are mixed. This might in part be explained by (1) differences in the sociodemographic (eg, age, ethnicity, migration, socioeconomic status) and clinical features of the samples studied, which often reflect inter-site differences in catchment area populations, type of early detection and intervention services involved, and potential sampling biases (particularly in CHR-P individuals²⁵); (2) the use of relatively small samples, which might result in type I and type II errors²⁶ and therefore limited generalizability of the findings; (3) heterogeneous image preprocessing protocols; and lastly (4)

the use of different inclusion criteria in different studies, leading to substantial heterogeneity in symptom severity and comorbidities.

To date, the majority of neuroimaging studies investigating abnormalities in the CHR-P and FEP populations have employed univariate analytical methods that allow statistical inferences at the group, rather than the individual level. Although univariate approaches are suited to detect focal abnormalities at a group level, differences in brain anatomy and functioning in the early stages of psychosis appear to be relatively subtle and widespread.^{5,27-29} Univariate approaches also involve multiple testing and the subsequent correction for multiple comparisons, which may be too conservative and not sensitive enough to detect alterations that are expressed at a network level rather than in a few distinct brain areas. The application of multivariate data-driven approaches, such as machine learning^{30,31} allows inferences to be made at the individual level, and therefore carry greater translational potential for application in clinical practice.^{32,33} In addition, multivariate approaches consider multiple voxels simultaneously and between-voxel correlations, rather than each voxel independently, and might therefore be better suited to detecting abnormalities at a network level, rather than focally.^{34,35}

Machine learning has been employed in the field of mental health to make predictions on a number of neurological and psychiatric conditions, including Alzheimer,³⁶ depression,^{37,38} anxiety disorders,³⁹ eating disorders,⁴⁰ and psychosis.^{6,10,33,41,42} (for critical reviews, please see Orrù et al,³⁰ Gifford et al,²² Vieira et al,³¹ Arbabshirani et al,²³ and Dwyer et al⁴³). In the context of psychosis, machine learning has been used to investigate different stages of illness ranging from psychosis risk,^{10,41,44} first episode of psychosis^{6,45} to established schizophrenia.⁴⁶ Studies have employed structural⁴⁴ and functional MRI data⁴⁷ but also nonimaging data⁴¹ to make predictions on broadly 3 areas: diagnosis, prognosis, and response to treatment. Aiding diagnosis classification is clinically helpful for some psychiatric conditions, such as anxiety disorders, or prodromal stages, where there is diagnostic uncertainty,^{36,44} while for other conditions, such as established schizophrenia, prediction of prognosis or response to treatment might be clinically more meaningful.^{6,33}

Studies on the early stages of psychosis, including both FEP and CHR-P individuals have generally shown accuracies above 75%.^{23,30,43} However, a recent study challenged the potential of machine learning for detecting changes in the early stages of psychosis. Using relatively large datasets of FEP patients, Vieira et al⁴⁵ reported lower classification accuracies than previous studies (between 50% and 70%), but also poor generalizability of models to other sites.⁴⁵ While the initial machine learning studies suggest that this approach holds some promise, they have involved relatively small groups

of subjects.^{4,10,44,48–51} This is important as the reliability of machine learning is directly affected by sample size, and overall accuracies are seen to decrease with sample size.²³ This suggests that results from previous studies, including studies on patients with psychosis, may not be generalizable, and so must be interpreted with caution.^{23,24} This also suggests that overfitting may be taking place; which is when a machine learning model is fitted to noise in the data rather than to an underlying pattern of interest. In this context, overfit models might give very high accuracies on the training data but will not generalize to new data. On the other hand, a negative correlation between sample size and accuracy might also be a sign of publication bias rather than overfitting.^{45,52} A further limitation of multivariate studies in the field to date is that in most cases, the findings have not been validated in an independent dataset.^{43,53} Finally, each lab tends to use its own pre-processing techniques and machine learning analytical approaches, adding further complexity/heterogeneity when comparing results from different studies.

Structural and functional brain changes are not the only objective measures that can be used to aid prediction of clinical outcome in psychosis. Indeed, evidence suggests that psychosis is associated with genetic changes^{54,55} as well as alterations in cognitive functioning.^{56–58} Therefore, integrating neuroimaging, biological, clinical, and cognitive data may facilitate the multimodal prediction of psychosis onset and clinical outcomes.^{42,59} In this context, multivariate analysis approaches such as machine learning, which can take into account simultaneously different clinically meaningful measures, have the potential of generating valid, clinically relevant, and usable prediction models. PSYSCAN (<http://psyscan.eu>) is a research program funded as part of the European Funding 7th Framework Programme that was designed to address the methodological issues described above, with the goal of translating findings from neuroimaging, genetics, clinical and cognitive measures from individuals in the early phase of psychosis (ie, CHR-P and FEP) into mainstream clinical practice.

PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice

PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis (ie, CHR-P and FEP stages) involving partners from the United Kingdom (London and Edinburgh), the Netherlands (Amsterdam, Maastricht, and Utrecht), Spain (Madrid and Santander), Denmark (Glostrup/Copenhagen), Germany (Marburg and Heidelberg), Ireland (Galway), Israel (Tel Aviv), Austria (Vienna), Switzerland (Zurich), Australia (Melbourne), Italy (Naples), plus affiliate sites in China (Hong Kong), Canada (Toronto), South Korea (Seoul), and Brazil (Sao Paulo). This consortium aims to recruit a large sample of CHR-P and FEP

participants and to collect a number of multimodal imaging measures (ie, structural, resting state functional MRI, and diffusion tensor imaging data), which will be integrated with psychopathological, sociodemographic, genetic, metabolomic, proteomic, immunological and cognitive data with the aim of improving outcome prediction. Data are being collected at first presentation and again at a number of follow-up timepoints, with the same instruments and methodological procedures being used at each site. A healthy control group is also being recruited and will serve as a comparative/control group for the CHR-P as well as for the FEP cohort.

Figure 1 and table 1 show the design of the PSYSCAN study. Supplementary material 1 provides a detailed overview of the sociodemographic information, clinical, and cognitive measures collected at the different follow-up timepoints.

Methodological Considerations in Multimodal Multicenter Studies

Multicenter studies provide a means of acquiring data from relatively large samples of subjects, representing different geographical areas. However, the involvement of several sites also introduces methodological challenges, particularly in controlling for the effects of site differences when acquiring imaging data. Table 2 lists some potential benefits and challenges that can arise when performing multicenter studies involving imaging acquisition.

Use of a Common Imaging Acquisition Protocol Across Sites

One of the major issues in multicenter neuroimaging studies are the effects of intersite variations in scanner make, model, and field strength.^{60–63} To minimize such effects, all sites in the PSYSCAN consortium used 3T scanners, adopted a common image acquisition protocol and underwent a site qualification procedure to ensure that the standard acquisition protocol could be implemented locally (supplementary materials 2). The site qualification was led by IXICO (<https://ixico.com>), the industrial partner in this project. The acquisition protocol includes published pulse-sequence design (ie, Alzheimer's Disease Neuroimaging Initiative ADNI-2 T1 and ADNI-3 FLAIR⁶⁴) and study-specific Diffusion Tensor Imaging (DTI) and resting state functional MRI sequences (supplementary materials 2).

Healthy Traveling Subjects Scanned at Different Sites

In the PSYSCAN study, although all sites are using scanners with the same field strength and harmonized acquisition parameters (supplementary materials 2), additional variability can still arise through the use of scanners that differ in model, manufacturer or specific features.^{60,65} The study has therefore included a travelling




Fig. 1. (a) Organization structure of the PSYSCAN Consortium in WorkPackages (WP). (b) Timelines of the Work-Packages in PSYSCAN.

subject study, an approach that has been previously adopted in other multicenter studies.^{65,66} Six healthy individuals have been scanned on 2 separate occasions using the PSYSCAN neuroimaging protocol, at 6 sites within the consortium. The data from these subjects will be used to quantify within- and between-scanner heterogeneity, to identify the determinants of this variance, to quantify the effects on the data, and to develop post-hoc calibration methods to attenuate these effects.

Recruitment at Different Sites

A further methodological challenge for multicenter studies is to ensure reliability of nonimaging data collection across multiple sites. Work-Package 5 (WP5) is responsible for collecting data from (1) CHR-P individuals, (2) FEP patients, and (3) healthy controls, in a naturalistic prospective design. Standardized and harmonized psychopathological, demographic, cognitive, and genetic measures are collected at baseline and during follow-up assessments. Researchers at each site completed both face-to-face and online training (<http://psyscan.eu>) on the instruments being used to screen and assess participants, including, but not limited to, the Positive and Negative Syndrome Scale,⁶⁷ a revised version of the Comprehensive Assessment of an At Risk

Mental State⁶⁸ which allows the additional scoring of the Structured Interview of Psychosis-Risk Syndromes⁶⁹ and the Schizophrenia Proneness Instrument for Adults.⁷⁰ To further ensure reliability across sites, particularly in the assessment of CHR-P participants, teleconferences to discuss all included cases take place every 1–2 months. Centralized monitoring and yearly on-site monitoring visits are also conducted to ensure that the protocols are being followed correctly, and to address any local issues related to subject assessment and follow-up. Cognitive function is assessed on iPads using tests derived from the CANTAB cognitive battery⁷¹ (ie paired associates learning, spatial span task, processing speed, emotion recognition task). These are brief computerized tests which participants perform using an iPad, with a total assessment time of around 20 minutes. Twenty minutes was chosen as a feasible time frame for clinical practice. The use of nonverbal rather than verbal tasks facilitates the use of the assessment in subjects with a wide range of native languages. Using a computerized assessment permits vocal instructions in the subject's native language to be embedded within the test (translation was done from English to the 10 other languages part of the consortium using a forward/backward translation method, and a check of the vocal instructions by a native speaker).⁷¹

Table 1. Aims and Expected Outcomes From PSYSCAN Work-Packages (WP)

Work-Package	Aim	Outcome
WP1. Management of the PSYSCAN project	To ensure (a) scientific dialogue and communication across the consortium and (b) efficient administration and reporting in accordance with EC guidelines and requirements	Overall organization and coordination of the PSYSCAN project and consortium
WP2. Merged legacy datasets	To collect, organize, analyze, and report on existing datasets collected by the consortium partners over the last 20 years from (a) patients with psychosis, (b) patients with genetic vulnerability for psychosis (22q11.2 deletion syndrome), (c) subjects at clinical high risk of psychosis (CHR-P), and (d) healthy controls	Development of new methods Data analysis on merged existing datasets New methods testing and validation
WP3. Development of software for data analysis	To design, code, assemble, document, and test new specialized software modules for machine learning, connectivity and network analysis	Development of new methods for the analysis or imaging, clinical, cognitive, and biological data Application of machine learning techniques on legacy and prospective data
WP4. Data management	Responsible for (a) the technical aspects of data management of both WP2 and WP5, (b) development of quality control protocols for imaging data collected as part of WP5	Large database with neuroimaging, demographic, cognitive and clinical data collected as part of WP5
WP5. Naturalistic prospective study	To collect new, homogenized data from (a) CHR-P individuals, (b) patients with first episode psychosis (FEP), and (c) healthy controls in a naturalistic prospective study comprising around 1000 subjects in total. Standardized and harmonized measures of neuroimaging, clinical, cognitive, biological, and genetic variables are collected at baseline and at follow-up to determine clinical and functional outcomes.	New longitudinal neuroimaging, cognitive, clinical, and biological measures collected from ~700 subjects (CHR-P, FEP, and HC)
WP6. Dissemination	To disseminate the activities and results of PSYSCAN, including the development of a website (psyscan.eu), annual stakeholder workshops for consultation and dissemination, production of leaflets, social media engagement (including Facebook and Twitter), publication of articles in scientific journals, and the organization of a final PSYSCAN conference	PSYSCAN website, publications, workshops, and conference

Table 2. Methodological Considerations in Multicenter Studies Involving Neuroimaging

	Benefits	Challenges
Use of a common imaging acquisition protocol across sites	Common imaging acquisition protocols and, wherever possible, published pulse-sequence design (eg, ADNI) minimize differences and allow for validation and replicability of the results	Site qualification is resource intensive and time consuming Standardized and on-going quality check to ensure that there are no changes to the MRI protocol is resource intensive and time consuming Compromise on acquisition protocols used, as not all sites have access to latest technology
Recruitment at different sites	Results are more representative of the overall patient population and therefore more generalizable Large number of participants leads to increased statistical power	Logistically and resource intensive Under-recruitment at single sites can be problematic in future analyses, particularly for neuroimaging analyses
Healthy traveling subjects scanned at different sites	Objective method to estimate and control for scanner variance	Logistically intensive, potentially expensive Jet lag can influence state of alertness and affect functional MRI
Use of legacy data	Develop and test new analytical methods Large dataset without recruitment costs	Due to the small group, generalizability can be questionable Data transfer and organization can be logistically and resource intensive Data handling difficulties such as partial information, missing data, lack of common measurements
Combining imaging and nonimaging data	Different measures can provide complementary information and therefore might facilitate prediction	New methods for the integration of different data type have to be developed High level of technical and statistical expertise needed to handle increased data complexity

Use of Legacy Data

In addition to the new data being acquired in WP5, existing data from previous studies have been collated from more than 3000 subjects, using 16 datasets from 9 of the consortium partners. These include structural MRI, DTI, and fMRI data, as well as nonimaging data (basic sociodemographic and clinical data), from patients with psychosis, patients with genetic vulnerability for psychosis (22q11.2 deletion syndrome), CHR-P individuals and healthy controls. These legacy data are being used to facilitate the development of novel machine learning algorithms that will be applied to the new datasets from WP5. These algorithms will initially be validated by dividing the samples into discovery and validation subsamples, and more definitively by testing the algorithms on analogous, independent datasets from other research consortia, through the *Harmonization of At Risk Multisite Observational Networks for Youth* (HARMONY) collaboration that includes the Personalised Prognostic Tool for early Psychosis Management (PRONIA—another EU-FP7 program) and 2 National Institute of Mental Health (NIMH)—funded programs, the North American Prodrome Longitudinal Study (NAPLS), and the Philadelphia Neurodevelopmental Cohort (PNC).

Combining Imaging and Nonimaging Data

One of the core aims of the project is to integrate neuroimaging, clinical, cognitive, and peripheral biomarker data to facilitate the prediction of psychosis onset, clinical and functional outcomes. Therefore, alongside clinical and cognitive data, blood samples (including whole blood, serum, and plasma) are collected for analyses of genomic, proteomic, metabolomic, and immune markers at baseline, 6 and 12 months in the CHR-P and HC cohorts and at baseline and 12 months in the FEP cohort. In particular, DNA will be extracted from whole blood for a GWAS analysis to allow the polygenic risk score for schizophrenia to be determined for each individual. A broad range of proteomic and metabolomic and immunological markers will be examined which can be readily determined from the frozen serum and plasma samples. Current markers in the literature have highlighted CFI and C6 proteins,⁷² reduced levels of essential polyunsaturated fatty acids⁷³ and increased levels of IL-6⁷⁴, however, this is a rapidly developing field so we will plan to undertake both an exploratory and hypothesis-led approach based on the most recent findings at the time of analysis.

To date, most predictive algorithms in psychosis have used data from a single modality, such as MRI data^{44,75} or clinical data.⁷⁶ The combination of imaging and nonimaging data may result in a more accurate model with higher predictive power compared with that of previous prediction tools,^{42,77} in particular, if different risk estimation tools are used in the context of a sequential and stepped assessment

to enrich the risk prediction.⁷⁷ With both legacy and newly collected data, supervised machine learning approaches³¹ will be used to predict clinically meaningful outcomes (eg, psychosis onset, social and role functioning, changes in symptom scores, and treatment response) from both neuroimaging and nonneuroimaging data. Similarly, unsupervised machine learning approaches^{31,78} will be used to identify subgroups of patients and investigate their clinical outcomes. These subgroups could potentially then be used to further inform supervised learning, for instance, by stratifying the subjects before making predictions.

Future Directions

Key steps for future progress in the field include the validation of prognostic and predictive algorithms in independent datasets from other projects (ie, external validation). Wide collaborations with other consortia such as HARMONY will provide the opportunity to initiate such endeavours. This independent validation of prognostic/predictive algorithms is critical to the ultimate identification of measures that can reliably predict psychosis onset in CHR-P individuals or clinical outcomes in those with a first episode of psychosis. For these measures to be embedded in day-to-day clinical practice they ideally should be collectable using methods that (1) are widely available, (2) do not require an excessive amount of patient or clinician time, and that (3) have a reasonable cost. This applies to some of the potentially useful measures in psychosis, such as MRI scanning or a blood sample for whole genome sequencing, whereas others may require technology that is relatively inaccessible (eg, positron emission tomography—PET-scanning) or analyses that are currently relatively expensive (eg, proteomics). It is therefore more likely that complex, multimodal, risk estimation algorithms would enter clinical routine only in a stepped risk assessment framework, in line with previous successful examples of clinical medicine (eg, cardiovascular and pulmonary⁷⁷).

Overall, PSYSCAN and similar large cohort studies are purposely designed to significantly contribute to the bench-to-bed approach and aim to develop clinically usable tools to predict psychotic illness onset and course, differential diagnosis, treatment response, and functional outcome, with practical implications for individualized treatment.

Supplementary Material

Supplementary data are available at *Schizophrenia Bulletin* online.

Funding

The PSYSCAN Project is supported by grant agreement no. 603196 under the European Union's Seventh Framework Programme.

Acknowledgments

We would like to thank all participants who took part in the study. *Conflict of Interest:* S.G. received honoraria, advisory board, or consulting fees from the following companies: Gedeon-Richter, Janssen Pharmaceuticals, Janssen-Cilag Polska Sp. z o.o, Otsuka, Pierre Fabre and Sunovion Pharmarmaceuticals. B.G. is the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. G.S. is president of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry, which is partially financed by the support from pharmaceutical companies. G.S. received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, AOP Orphan, Alkermes, Janssen, Lundbeck, Pfizer. PFP received advisory board fees and research funds from Lundbeck.

References

- Mechelli A, Riecher-Rössler A, Meisenzahl EM, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. *Arch Gen Psychiatry*. 2011;68(5):489–495.
- Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet*. 2003;361(9354):281–288.
- Tognin S, Riecher-Rössler A, Meisenzahl EM, et al. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. *Psychol Med*. 2014;44(3):489–498.
- Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. *Schizophr Bull*. 2015;41(2):471–482.
- Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis—a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2010;34(8):1207–1222.
- Koutsouleris N, Kahn RS, Chekroud AM, et al. Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. *Lancet Psychiatry*. 2016;3(10):935–946.
- de Wit S, Ziermans TB, Nieuwenhuis M, et al. Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. *Hum Brain Mapp*. 2017;38(2):704–714.
- Nieuwenhuis M, Schnack HG, van Haren NE, et al. Multi-center MRI prediction models: predicting sex and illness course in first episode psychosis patients. *Neuroimage*. 2017;145(Pt B):246–253.
- Amminger GP, Mechelli A, Rice S, et al. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. *Transl Psychiatry*. 2015;5:e495.
- Tognin S, Pettersson-Yeo W, Valli I, et al. Using structural neuroimaging to make quantitative predictions of symptom progression in individuals at ultra-high risk for psychosis. *Front Psychiatry*. 2013;4:187.
- Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). *Mol Psychiatry*. 2018;23(11):2145–2155.
- Bosson MG, Antoniadou M, Azis M, et al. Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis. *JAMA Psychiatry*. 2018.
- Fusar-Poli P, Cappucciati M, Bonoldi I, et al. Prognosis of brief psychotic episodes: a meta-analysis. *JAMA Psychiatry*. 2016;73(3):211–220.
- Fusar-Poli P, Cappucciati M, Borgwardt S, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. *JAMA Psychiatry*. 2016;73(2):113–120.
- Davies C, Radua J, Cipriani A, et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. *Front Psychiatry*. 2018;9:187.
- Davies C, Cipriani A, Ioannidis JPA, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. *World Psychiatry*. 2018;17(2):196–209.
- Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. *Ther Adv Psychopharmacol*. 2018;8(11):303–318.
- Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry*. 2017;174(10):927–942.
- Butcher NJ, Fung WL, Fitzpatrick L, et al. Response to clozapine in a clinically identifiable subtype of schizophrenia. *Br J Psychiatry*. 2015;206(6):484–491.
- Morrison AP, Pyle M, Gumley A, et al.; FOCUS trial group. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. *Lancet Psychiatry*. 2018;5(8):633–643.
- Schooler NR. Cognitive behavioural therapy for clozapine non-responders. *Lancet Psychiatry*. 2018;5(8):607–608.
- Gifford G, Crossley N, Fusar-Poli P, et al. Using neuroimaging to help predict the onset of psychosis. *Neuroimage*. 2017;145(Pt B):209–217.
- Arbabshirani MR, Plis S, Sui J, Calhoun VD. Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls. *Neuroimage*. 2017;145(Pt B):137–165.
- Janssen RJ, Mourao-Miranda J, Schnack HG. Making individual prognoses in psychiatry using neuroimaging and machine learning. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018;3(9):798–808.
- Fusar-Poli P, Schultze-Lutter F, Cappucciati M, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. *Schizophr Bull*. 2016;42(3):732–743.
- Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci*. 2013;14(5):365–376.

27. Egerton A, Borgwardt S, Tognin S, Howes OD, McGuire P, Allen P. An overview of functional, structural, neurochemical imaging studies in individuals with a clinical high risk for psychosis. *Neuropsychiatry*. 2011;1(5):477–493.
28. Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naïve VBM studies. *Schizophr Bull*. 2012;38(6):1297–1307.
29. Das T, Borgwardt S, Hauke DJ, et al. Disorganized gyrification network properties during the transition to psychosis. *JAMA Psychiatry*. 2018;75(6):613–622.
30. Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. *Neurosci Biobehav Rev*. 2012;36(4):1140–1152.
31. Vieira S, Pinaya WH, Mechelli A. Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: methods and applications. *Neurosci Biobehav Rev*. 2017;74(Pt A):58–75.
32. Fusar-Poli P, Hijazi Z, Stahl D, Steyerberg EW. The science of prognosis in psychiatry: a review. *JAMA Psychiatry*. 2018;75(12):1289–1297.
33. Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. *JAMA Psychiatry*. 2018;75(11):1156–1172.
34. Lao Z, Shen D, Xue Z, Karacali B, Resnick SM, Davatzikos C. Morphological classification of brains via high-dimensional shape transformations and machine learning methods. *Neuroimage*. 2004;21(1):46–57.
35. Norman KA, Polyn SM, Detre GJ, Haxby JV. Beyond mind-reading: multi-voxel pattern analysis of fMRI data. *Trends Cogn Sci*. 2006;10(9):424–430.
36. Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM. Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. *Neurobiol Aging*. 2008;29(4):514–523.
37. Fu CH, Mourao-Miranda J, Costafreda SG, et al. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. *Biol Psychiatry*. 2008;63(7):656–662.
38. Kambeitz J, Cabral C, Sacchet MD, et al. Detecting neuroimaging biomarkers for depression: a meta-analysis of multivariate pattern recognition studies. *Biol Psychiatry*. 2017;82(5):330–338.
39. Hilbert K, Lueken U, Muehlhan M, Beesdo-Baum K. Separating generalized anxiety disorder from major depression using clinical, hormonal, and structural MRI data: a multimodal machine learning study. *Brain Behav*. 2017;7(3):e00633.
40. Lavagnino L, Amianto F, Mwangi B, et al. Identifying neuroanatomical signatures of anorexia nervosa: a multivariate machine learning approach. *Psychol Med*. 2015;45(13):2805–2812.
41. Mechelli A, Lin A, Wood S, et al. Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis. *Schizophr Res*. 2017;184:32–38.
42. Pettersson-Yeo W, Benetti S, Marquand AF, et al. Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. *Psychol Med*. 2013;43(12):2547–2562.
43. Dwyer DB, Falkai P, Koutsouleris N. Machine learning approaches for clinical psychology and psychiatry. *Annu Rev Clin Psychol*. 2018;14:91–118.
44. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. *Arch Gen Psychiatry*. 2009;66(7):700–712.
45. Vieira S, Gong QY, Pinaya WH, et al. Using machine learning and structural neuroimaging to detect first episode psychosis: reconsidering the evidence. *Schizophr Bull*. 2019.
46. Shen H, Wang L, Liu Y, Hu D. Discriminative analysis of resting-state functional connectivity patterns of schizophrenia using low dimensional embedding of fMRI. *Neuroimage*. 2010;49(4):3110–3121.
47. Kalmady SV, Greiner R, Agrawal R, et al. Towards artificial intelligence in mental health by improving schizophrenia prediction with multiple brain parcellation ensemble-learning. *NPJ Schizophr*. 2019;5(1):2.
48. Valli I, Marquand AF, Mechelli A, et al. Identifying individuals at high risk of psychosis: predictive utility of support vector machine using structural and functional MRI data. *Front Psychiatry*. 2016;7:52.
49. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Möller HJ, Riecher-Rössler A. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. *Schizophr Bull*. 2012;38(6):1234–1246.
50. Koutsouleris N, Davatzikos C, Bottlender R, et al. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. *Schizophr Bull*. 2012;38(6):1200–1215.
51. Bak N, Ebdrup BH, Oranje B, et al. Two subgroups of antipsychotic-naïve, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. *Transl Psychiatry*. 2017;7(4):e1087.
52. Mendelson AF, Zuluaga MA, Lorenzi M, Hutton BF, Ourselin S; Alzheimer's Disease Neuroimaging Initiative. Selection bias in the reported performances of AD classification pipelines. *Neuroimage Clin*. 2017;14:400–416.
53. Studerus E, Ramyead A, Riecher-Rössler A. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. *Psychol Med*. 2017;47(7):1163–1178.
54. Kéri S, Kiss I, Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. *Mol Psychiatry*. 2009;14(2):118–119.
55. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. *Transl Psychiatry*. 2012;2:e82.
56. Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. *Front Psychiatry*. 2014;4:182.
57. Barch DM, Sheffield JM. Cognitive impairments in psychotic disorders: common mechanisms and measurement. *World Psychiatry*. 2014;13(3):224–232.
58. Kambeitz-Ilankovic L, Haas SS, Meisenzahl E, et al. Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: a pattern recognition study. *Neuroimage Clin*. 2019;21:101624.
59. Zarogianni E, Storkey AJ, Borgwardt S, Smieskova R, Studerus E, Riecher-Rössler A, Lawrie SM. Individualized prediction of psychosis in subjects with an at-risk mental state. *Schizophr Res*. 2017;S0920-9964(17):30537–6.

60. Jovicich J, Czanner S, Han X, et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. *Neuroimage*. 2009;46(1):177–192.
61. Kruggel F, Turner J, Muftuler LT; Alzheimer's Disease Neuroimaging Initiative. Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. *Neuroimage*. 2010;49(3):2123–2133.
62. Vogelbacher C, Möbius TWD, Sommer J, et al. The Marburg-Münster Affective Disorders Cohort Study (MACS): a quality assurance protocol for MR neuroimaging data. *Neuroimage*. 2018;172:450–460.
63. Reig S, Sánchez-González J, Arango C, et al. Assessment of the increase in variability when combining volumetric data from different scanners. *Hum Brain Mapp*. 2009;30(2):355–368.
64. Initiative AsDN. ADNI | MRI acquisition—Alzheimer's disease neuroimaging initiative. <http://adni.loni.usc.edu/methods/mri-tool/mri-acquisition/>.
65. Schnack HG, van Haren NE, Brouwer RM, et al. Mapping reliability in multicenter MRI: voxel-based morphometry and cortical thickness. *Hum Brain Mapp*. 2010;31(12):1967–1982.
66. Cannon TD, Sun F, McEwen SJ, et al. Reliability of neuro-anatomical measurements in a multisite longitudinal study of youth at risk for psychosis. *Hum Brain Mapp*. 2014;35(5):2424–2434.
67. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13(2):261–276.
68. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry*. 2005;39(11–12):964–971.
69. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 2003;29(4):703–715.
70. Schultze-Lutter F, Ruhrmann S, Pickler H, Klosterkötter J. Development and evaluation of the schizophrenia proneness instrument, adult version (SPI-A). *Schizophr Res*. 2006;86 supplement(S4-S5).
71. Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD. Assessing cognitive function in clinical trials of schizophrenia. *Neurosci Biobehav Rev*. 2010;34(8):1161–1177.
72. Focking M, Pollak T, Dicker P, et al. Proteomic analysis of blood based samples from the OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe) study point towards complement pathway protein changes. *Schizophr Bull*. 2018;44(suppl 1):S74–S75.
73. Davison J, O'Gorman A, Brennan L, Cotter DR. A systematic review of metabolite biomarkers of schizophrenia. *Schizophr Res*. 2018;195:32–50.
74. Orlovska-Waast S, Kohler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2018;24(6):869–887.
75. Dazzan P, Arango C, Fleischacker W, et al. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. *Schizophr Bull*. 2015;41(3):574–583.
76. Cannon TD, Yu C, Addington J, et al. An individualized risk calculator for research in prodromal psychosis. *Am J Psychiatry*. 2016;173(10):980–988.
77. Schmidt A, Cappucciati M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. *Schizophr Bull*. 2017;43(2):375–388.
78. Dwyer DB, Cabral C, Kambeitz-Ilankovic L, et al. Brain subtyping enhances the neuroanatomical discrimination of schizophrenia. *Schizophr Bull*. 2018;44(5):1060–1069.

The PSYSCAN Consortium

Philip McGuire^{1,2}, Stefania Tognin¹, Paolo Fusar-Poli^{1,2}, Matthew Kempton¹, Gemma Modinos¹, Kate Merritt¹, Andrea Mechelli¹, Paola Dazzan¹, George Gifford¹, Natalia Petros¹, Mathilde Antoniadou¹, Andrea De Micheli¹, Sandra Vieira¹, Tom J Spencer¹, Cristina Scarpazza¹, Emily Hird¹, Rene Kahn^{3,4}, Arija Maat³, Erika van Hell³, Inge Winter³, Wiepke Cahn³, Hugo Schnack³, Lieuwe de Haan⁵, Dieuwke Siegemann⁵, Jana Barkhof⁵, Lotte Hendriks⁵, Iris de Wit⁵, Benedicto Crespo-Facorro^{6,7}, Diana Tordesillas-Gutierrez^{6,7}, Esther Setien-Suero^{6,7}, Rosa Ayesa-Arriola^{6,7}, Paula Suarez-Pinilla^{6,7}, MariaLuz Ramirez-Bonilla^{6,7}, Victor Ortiz Garcia-de la foz^{6,7}, Birte Glenthøj^{8,9}, Mikkel Erlang Sørensen⁸, Karen Tangmose^{8,9}, Helle Schæbel⁸, Brian Broberg⁸, Egill Rostrup^{8,10}, Stephen Lawrie¹¹, Colm McDonald¹², Brian Hallahan¹², Dara Cannon¹², James McLoughlin¹², Martha Finnegan¹², Oliver Gruber¹³, Therese van Amelsvoort^{14,15}, Danny Deckers^{14,15}, Machteld Marcelis^{14,15}, Claudia Vingerhoets¹⁴, Celso Arango¹⁶, Covadonga M. Diaz-Caneja¹⁶, Miriam Ayora¹⁶, Joost Janssen¹⁶, Roberto Rodríguez-Jiménez¹⁷, Marina Díaz-Marsá¹⁸, Tilo Kircher¹⁹, Irina Falkenberg¹⁹, Florian Bitsch¹⁹, Philipp Berger¹⁹, Jens Sommer^{19,20}, Kyeon Raab¹⁹, Babette Jakobi¹⁹, Barnaby Nelson^{21,22}, Patrick McGorry^{21,22}, Paul Amminger^{21,22}, Meredith McHugh^{21,22}, Silvana Galderisi²³, Armida Mucci²³, Paola Bucci²³, Giuseppe Piegari²³, Daria Pietrafesa²³, Alessia Nicita²³, Sara Patriarca²³, Rodrigo Bressan²⁴, André Zugman²⁴, Ary Gadelha²⁴, Gracielle Rodrigues da Cunha²⁴, Jun Soo Kwon²⁵, Kang Ik Kevin Cho²⁵, Tae Young Lee²⁵, Minah Kim²⁵, Yoo Bin Kwak²⁵, Wu Jeong Hwang²⁵, Mark Weiser²⁶, Romina Mizrahi^{27,28,29}, Michael Kiang^{27,28,29}, Cory Gerritsen^{28,29}, Margaret Maheandiran²⁸, Sarah Ahmed^{27,28}, Ivana Prce²⁸, Jenny Lepock^{27,28}, Gabriele Sachs³⁰, Matthäus Willeit³⁰, Marzena Lenczowski³⁰, Ullrich Sauerzopf³⁰, Ana Weidenauer³⁰, Julia Furtner-Srajer³¹, Matthias Kirschner^{32,33}, Anke Maatz³², Achim Burre³², Philipp Stämpfli³², Naemi Huber³², Stefan Kaiser^{34,35}, Wolfram Kawohl³⁶, Michael Brammer³⁸, Jonathan Young^{39,1}, Edward Bullmore⁴⁰, and Sarah Morgan⁴⁰

Affiliations

1. Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
2. National Institute for Health Research, Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK
3. University Medical Center, Division of Neurosciences, Department of Psychiatry, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
4. Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029–6574
5. Amsterdam UMC, University of Amsterdam, Psychiatry, Department Early Psychosis, Meibergdreef 9, Amsterdam, The Netherlands
6. CIBERSAM, Department of Psychiatry, University Hospital Virgen del Rocío, Sevilla; Marqués de Valdecilla University

- Hospital, IDIVAL. School of Medicine, University of Cantabria, Santander, Spain
7. CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Spain
 8. Centre for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark
 9. University of Copenhagen, Faculty of Health and Medical Sciences, Dept. of Clinical Medicine, Copenhagen, Denmark
 10. Functional Imaging Unit (FIUNIT), Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark
 11. Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK
 12. Centre for Neuroimaging & Cognitive Genomics (NICOG), NCBES Galway Neuroscience Centre, National University of Ireland Galway, H91 TK33 Galway, Ireland
 13. Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Heidelberg University, Heidelberg, Germany
 14. Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
 15. GGZE Mental Health Care, Eindhoven, the Netherlands
 16. Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, Spain; Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain
 17. Departamento de Psiquiatría, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; CIBERSAM (Biomedical Research Networking Centre in Mental Health), Spain
 18. Hospital Clínico de San Carlos, Universidad Complutense, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, España
 19. Dept of Psychiatry, University of Marburg, Rudolf-Bultmann-Straße 8, D-35039, Marburg, Germany
 20. Core-Facility Brainimaging, Faculty of Medicine, University of Marburg
 21. Orygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road, Parkville, Victoria, Melbourne, Australia
 22. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
 23. Department of Psychiatry, University of Campania Luigi Vanvitelli, Largo Madonna delle Grazie, 80138, Naples, Italy
 24. Department of Psychiatry, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil
 25. Department of Psychiatry, Seoul National University College of Medicine, 101 Dahakno, Jongno-gu, Seoul, Korea
 26. Department of Psychiatry, Sheba Medical Center, Tel Hashomer 52621, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
 27. Institute of Medical Science, University of Toronto, 1 King's College Circle Room 2374, Toronto, Ontario, Canada M5S 1A8
 28. Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
 29. Department of Psychiatry, University of Toronto, 250 College Street 8th Floor, Toronto, Ontario, Canada M5T 1R8
 30. Department of Psychology, University of Toronto, 100 St. George Street 4th Floor, Toronto, Ontario, Canada M5S 3G3
 31. Department of Psychiatry and Psychotherapy, 1090 Vienna, Austria
 32. Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy Währingergürtel 18–20, 1090 Vienna
 33. Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland
 34. Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
 35. Clinical and Experimental Psychopathology Laboratory, Faculty of Medicine, University of Geneva, Switzerland
 36. Adult Psychiatry Division, Department of mental health and psychiatry, University Hospitals of Geneva, Switzerland
 37. Department for Psychiatry and Psychotherapy, Psychiatric Services Aargau, Brugg, Switzerland
 38. Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
 39. IXICO plc, London, UK
 40. Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK